Products manufactured at the new Vaughan facility will support research in areas including cancer, infectious disease, mental health, and environmental safety
Program provides access to Lilly-trained artificial intelligence to help accelerate breakthrough medicines
MKP11093 has shown strong results in preclinical studies with a promising safety and selectivity profile
It will focus on interface between API and formulation manufacturing, reducing carbon footprint in formulation production, creating intellectual property, training next-generation scientists, and setting new industry benchmarks
These licenses are given in areas of infectious disease diagnostics, immunodiagnostics, and vaccine development
It offers clear environmental benefits, lower emissions, reduced hazardous material use, and alignment with circular economy goals
Facility designed to advance the next generation of imaging systems
Protein L is known as a “superantigen” because it can bind antibodies in unusual ways
The ‘265 Patent is based on Enanta’s July 2020 patent application describing coronavirus protease inhibitors invented by Enanta scientists
New platform powered by Opentrons expands lab automation to accelerate scientific discovery
Subscribe To Our Newsletter & Stay Updated
